SCHEMBL1907229

SCHEMBL1907229

Cc1ccccc1C(=O)c1ccc(Nc2cccc(F)c2C)cc1Cl

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 15/20 0.76
MAPK13 O15264 14/20 0.76
MAPK12 P53778 14/20 0.76
MAPK11 Q15759 14/20 0.76
AVPR2 P30518 1/20 0.46
OXTR P30559 1/20 0.46
AVPR1A P37288 1/20 0.46
GRM4 Q14833 1/20 0.45
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
USP2 O75604 1/20 0.42
MT-CO2 P00403 1/20 0.42
LMNA P02545 1/20 0.42
TTR P02766 1/20 0.42
PLA2G1B P04054 1/20 0.42
CYP1A2 P05177 1/20 0.42
PGR P06401 1/20 0.42
CYP3A4 P08684 1/20 0.42
HTR1A P08908 1/20 0.42
ADRA2A P08913 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1907450 0.92 MAPK14 (0.81) MAPK14MAPK13MAPK12MAPK11AVPR2
SCHEMBL7199694 0.89 MAPK14 (0.73) MAPK14MAPK13MAPK12MAPK11AVPR2
SCHEMBL7073452 0.88 MAPK14 (0.73) MAPK14MAPK13MAPK12MAPK11AVPR2
SCHEMBL1904637 0.86 MAPK14 (1.00) MAPK14MAPK13MAPK12MAPK11AVPR2
SCHEMBL1907051 0.86 MAPK14 (0.55) MAPK14MAPK13MAPK12MAPK11AVPR2
SCHEMBL2198124 0.86 MAPK14 (0.56) MAPK14MAPK13MAPK12MAPK11AVPR2
SCHEMBL2196661 0.86 MAPK14 (0.56) MAPK14MAPK13MAPK12MAPK11AVPR2
SCHEMBL1906421 0.85 MAPK14 (0.87) MAPK14MAPK13MAPK12MAPK11AVPR2
SCHEMBL7196446 0.85 MAPK14 (0.72) MAPK14MAPK13MAPK12MAPK11AVPR2
SCHEMBL7197711 0.84 MAPK14 (0.73) MAPK14MAPK13MAPK12MAPK11GRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4684515-B2 2011-05-18 JP claimed
EP-1237845-B1 AMINOBENZOPHENONES AS INHIBITORS OF IL-1BETA AND TNF-ALPHA LEO PHARMA AS (DK) 2007-05-23 EP claimed
US-6541670-B2 Antiinflammatory agents LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) 2003-04-01 US claimed
US-20030013770-A1 Aminobenzophenones as inhibitors of il 1b and tnf LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) 2003-01-16 US claimed
US-20020165286-A1 Dermal anti-inflammatory composition LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) 2002-11-07 US claimed
EP-1237845-A1 AMINOBENZOPHENONES AS INHIBITORS OF IL-1BETA AND TNF-ALPHA LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LOVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB) (DK) 2002-09-11 EP claimed
WO-2002045752-A2 DERMAL ANTI-INFLAMMATORY COMPOSITION LEO PHARMA A/S (DK) 2002-06-13 WO claimed
WO-2001042189-A1 AMINOBENZOPHENONES AS INHIBITORS OF IL-1β AND TNF-$g(a) LEO PHARMA A/S (DK) 2001-06-14 WO claimed
US-8293772-B2 Triazole substituted aminobenzophenone compounds LEO PHARMA A/S (DK) 2012-10-23 US disclosed
EP-1658263-B9 NOVEL AMINOBENZOPHENONE COMPOUNDS LEO PHARMA AS (DK) 2011-11-09 EP disclosed
US-7977387-B2 Aminobenzophenone compounds LEO PHARMA A/S (DK) 2011-07-12 US disclosed
EP-1658263-B1 NOVEL AMINOBENZOPHENONE COMPOUNDS LEO PHARMA AS (DK) 2010-06-02 EP disclosed
EP-1828148-B1 TRIAZOLE SUBSTITUTED AMINOBENZOPHENONE COMPOUNDS LEO PHARMA AS (DK) 2010-01-20 EP disclosed
EP-1828148-A1 TRIAZOLE SUBSTITUTED AMINOBENZOPHENONE COMPOUNDS Leo Pharma A/S (DK) 2007-09-05 EP disclosed
US-6541670-B2 Antiinflammatory agents LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) 2003-04-01 US disclosed
US-20030013770-A1 Aminobenzophenones as inhibitors of il 1b and tnf LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) 2003-01-16 US disclosed
US-20020165286-A1 Dermal anti-inflammatory composition LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) 2002-11-07 US disclosed
EP-1237845-A1 AMINOBENZOPHENONES AS INHIBITORS OF IL-1BETA AND TNF-ALPHA LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LOVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB) (DK) 2002-09-11 EP disclosed
WO-2002045752-A2 DERMAL ANTI-INFLAMMATORY COMPOSITION LEO PHARMA A/S (DK) 2002-06-13 WO disclosed
WO-2001042189-A1 AMINOBENZOPHENONES AS INHIBITORS OF IL-1β AND TNF-$g(a) LEO PHARMA A/S (DK) 2001-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030013770-A1 Aminobenzophenones as inhibitors of il 1b and tnf IL1B, IL1A, IL6 MAPK14 1553/4885MAPK13 2221/4885MAPK12 1892/4885
US-20020165286-A1 Dermal anti-inflammatory composition CUTA, IL1B, LRBA MAPK14 644/4885MAPK13 1521/4885MAPK12 1535/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.